ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer
Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib [...]
Axitinib effective as a third-line treatment for kidney cancer
A recent study published in the journal In Vivo assessed [...]
Promising efficacy and safety of seleno-L-methionine plus axitinib in advanced kidney cancer
Data from a recent phase I study of seleno-L-methionine in [...]
Axitinib first-line treatment of papillary renal cell carcinoma
The majority of renal cell carcinomas (RCCs) are a subtype [...]
Individualised axitinib dosing for patients with metastatic kidney cancer
In the following video interview with Practice Update, Dr Nancy [...]
Evaluation of brain metastases in patients with kidney cancer treated with avelumab plus axitinib
In this video interview from Practice Update, Dr Eric Jonasch [...]
ASCO GU 2020: Immunotherapy combinations effective for brain metastases
Two small studies reported on patients whose kidney cancer had [...]
NICE draft guidance refuses pembrolizumab plus axitinib combination
The National Institute for Health and Care Excellence (NICE) have issued [...]
New first-line immunotherapy plus TKI combinations for metastatic kidney cancer
Approval of axitinib plus pembrolizumab and axitinib plus avelumab in [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
